Pfizer's Sutent fails Phase III colorectal cancer trial
02 July 2009
Malini Guha
Please Login to read the full article.
02 July 2009
Malini Guha
Pfizer's Sutent (sunitinib) has been dealt another significant blow after failing its first Phase III trial in advanced colorectal cancer. This could have been Pfizer's lead anticancer's biggest indication to date.
The 720-patient first-line trial, SUN 1122, was discontinued after...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Immatics receives Pfizer's 'support' for pivotal IMA901 trial in RCC
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- Pfizer's Sutent wins US FDA's OK in rare pancreatic cancer
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
